BRIEF published on 08/27/2024 at 13:05, 2 years 1 month ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 2 years 1 month ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 2 years 1 month ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 2 years 3 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years 3 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years 3 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 2 years 3 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 2 years 3 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 2 years 3 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 2 years 5 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 10/14/2026 at 15:40, 3 hours 52 minutes ago Galway Metals Announces Closing of $14 Million Brokered Private Placement Led by Michael Gentile
Published on 10/14/2026 at 15:00, 4 hours 32 minutes ago Route1 Provides Operating and Market Update; Outlines Q4 2026 Priorities
Published on 10/14/2026 at 15:00, 4 hours 32 minutes ago Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Published on 10/14/2026 at 14:50, 4 hours 42 minutes ago AIAI Holdings to Present at the 20th Annual LD Micro Main Event
Published on 10/14/2026 at 14:30, 5 hours 2 minutes ago Boron One Holdings Inc. Announces Positive Preliminary Economic Assessment (PEA) for Its Piskanja Boron Project
Published on 10/14/2026 at 19:05, 26 minutes ago Bulgin Introduces 6000 Series Hybrid Buccaneer Connectors for Power and Signal Connectivity
Published on 10/14/2026 at 18:43, 49 minutes ago Jean-Marc Bellaiche to become new CEO of the DOUGLAS Group - Sander van der Laan to retire
Published on 10/14/2026 at 18:42, 50 minutes ago EQS-Adhoc: DOUGLAS AG: Supervisory Board appoints Jean-Marc Bellaiche as Chief Executive Officer; Alexander van der Laan to leave the Management Board
Published on 10/14/2026 at 18:00, 1 hour 32 minutes ago CIS : Chiffre d’affaires du 3ème trimestre 2026 supérieur aux attentes : accélération de la croissance et visibilité renforcée.
Published on 10/14/2026 at 18:00, 1 hour 32 minutes ago CIS : Q3 2026 revenue higher than expected: accelerated growth and increased visibility.
Published on 10/14/2026 at 17:40, 1 hour 52 minutes ago Mersen obtient la certification internationale Living Wage pour son engagement en faveur du bien-être de ses collaborateurs
Published on 10/14/2026 at 17:40, 1 hour 52 minutes ago Mersen’s commitment to employee well-being earns it international Living Wage certification
